Albila

Investments
company-building

Strategic Investments

Albila

Albila, which set out with the vision of being a pioneer and leader in Antiserum, biotechnological product development and R&D activities in Turkey, was established as an "Angel Investment" project.

Year of Establishment & Headquarters 2017, Eskişehir
Year of Entry into Ecosystem 2018
Shareholding Structure
Inveo Yatırım Holding 1,21%
Sectors Pharmaceutical and Serum Production and Trade
Countries Türkiye

HIGHLIGHTS

We are working for the realization of developments that can be beneficial for human and human health without harming the ecosystem.

Albila was established in 2017 with an "Angel Investment" project. The shareholder structure consists of a total of 40 people from Turkey's leading businesswomen and businessmen. It is the first drug production facility in Eskişehir, which plans to produce horse-derived antidotes against animal stings without harming the ecosystem.

Albila Headquarters is in Istanbul, in Eskişehir Organized Industrial Zone; Production facility in GMP standards, within the body of Osmangazi University; scorpion venom production unit in Mahmudiye; There is a horse care and immunization unit.

The company carries out R&D studies with Eskişehir Osmangazi University within the scope of University-Industry cooperation, and on this occasion provides academic support from international universities. The facility consisting of 1600 square meters of R&D, P&D and clean room; It has a young and dynamic team of chemists, molecular biologists and pharmacists.

alt